



Around the world of US healthcare in 360 words or less



April 20, 2026 | Issue 413

Editor's note

[This series](#) is produced by KPMG Healthcare and is intended to be short and succinct, less than 360 words, to provide a weekly digestible bite of healthcare regulatory, policy, and industry news relevant to our clients. Links are provided to source material (proposed and final regulations, agency guidance and press releases, reports, research, etc.) when available. Please share this email with colleagues and other interested individuals, and encourage them to [subscribe to our mailing list here](#).

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

[Subscribe here](#)



Healthcare regulatory news

The Trump administration has [accepted](#) over 150 companies into the new [ACCESS model](#), which increases Medicare reimbursement for AI and tech-driven healthcare solutions that improve patient outcomes. The agency recently extended the deadline to May 15 to apply for the first cohort and noted that accepted companies must still meet

further requirements, like becoming a Medicare Part B-enrolled provider, to guarantee participation.

Building on [existing](#) interoperability regulations, CMS has [proposed](#) to mandate electronic prior authorization for prescription drugs for payers in MA, Medicaid, CHIP, and on the federal exchanges. [According to the agency](#), the regulation intends to accelerate patient access to medications by shortening decision timeframes and increasing process transparency, with a proposed compliance date of October 1, 2027.

An FDA advisory committee will [convene](#) to [reconsider](#) allowing compounding pharmacies to produce certain previously banned injectable peptides, while the agency concurrently [weighs](#) broadening its "new dietary ingredient" scope to include peptides. Spurred by industry lobbying and consumer advocacy, these potential regulatory shifts have provoked [debates](#) among stakeholders regarding the appropriate guidelines for evaluating the safety and effectiveness of these products.



Healthcare law and policy news

President Trump has [nominated](#) Erica Schwartz, a physician and former deputy surgeon general and retired member of the Public Health Service Commissioned Corps, to lead the CDC. She is [slated](#) to replace NIH Director Bhattacharya who was serving as acting CDC director after the [departure](#) of the agency's previous director.

Maryland's Prescription Drug Affordability Board [established](#) an upper payment limit for the diabetes medication Jardiance, marking just the [second](#) instance a state board has implemented a drug price cap. The policy takes effect in January 2027 and is [projected](#) to yield \$320,000 in annual savings.

According to a [study](#) in JAMA study found that hospitals serving more low-income and minority patients were less likely to comply with CMS's Hospital Price Transparency [rule](#), likely due to resource and technology constraints. Notably, compliant hospitals charged higher fees for certain procedures, suggesting noncompliance was not driven by intent to conceal prices. The researchers suggest CMS consider complementing enforcement with technical support and targeted IT funding for under-resourced hospitals.



Please send your questions or comments to us-hclspractice@kpmg.com.

KPMG. Make the Difference.

Learn about us:



[kpmg.com](https://www.kpmg.com)



Subscribe

Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.

[Privacy](#) | [Legal](#)

You have received this message from KPMG LLP. If you wish to unsubscribe from this publication or from other KPMG communications, please click [here](#) to visit your KPMG Communication Preferences Center. To unsubscribe from all KPMG communications, click [here](#).

© 2026 KPMG LLP, a Delaware limited liability partnership, and its subsidiaries are part of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.

USCS035556-1A